
Pharma Marketing Blog represents the opinions of John Mack Publisher of Pharma Marketing News.
We accept advertising relevant to the interests of our members. For more information, see:
Media Kit
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
|

Readers' Favorites
| Return to All Pharma Marketing Blog Topics |
"John- really enjoy your daily emails and especially the blogs. Very well written. The one today on ED was a classic. One might even say penetrating observations... Keep up the good work." -- JJ
If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
The following posts are the most popular based on monthly views and/or comments received. Listed in reverse chronological order:
- It Was Politics That Killed Avandia, Says Glaxo
- Alli Newspeak: Oily Spotting is "Treatment Effect"
- SiCKO is Boffo but Not Anti-Pharmaco, per se
- Avandia Hearing Soap Opera: Ethics, Demagogy, Sensationalism, and Threats by GSK
- Vytorin Ads Are Getting Old -- and Disturbing!
- Merck Quits Lobbying for Mandatory Gardasil Vaccination
- When is a Free Lunch More Than Just Lunch?
- Blogs vs. DTC: What's Best for Consumers?
- Dollars for Docs: More Scrutiny Needed
- The Zubillaga Affair: Effect on the Prospects for Pharma Blogging
- Basics of Sales Rep Watching
- Takeda - Fire These Guys!
- Call for a Rozerem Prescription Boycott!
- Drug Safety - A Mere Asterisk to the FDA
- Vytorin Ads Are Getting Old -- and Disturbing!
- Merck Quits Lobbying for Mandatory Gardasil Vaccination
- God Bless R&D, but Marketers May Go to Hell!
- Alli Oops! I Just Pooped Myself!
- First Ever Pharma Blogosphere Survey!
- Prilosec OTC Bunco Artists
- Banned from CafePharma!
- Are Sales Reps Necessary?
- What Was Blogworthy in 2006? A Review
- torcetrapib: "$800 Million" Failure but Kindler Safe
- Am I Dreaming, or Is This a Rozerem Ad?
- Levitra Levity
- The "Girl from Google"
- Interpretation of Ads: Hokey vs. Horny
- Lipitor's Jarvik: Fop or Flop?
- Interpretation of Ads: Hokey vs. Horny
- Marketing Executive Salaries
- Another Pharma CEO Bites the Dust!
- Kindler, Cheney: Kindred Spirits?
- WLF: A No-Risk Ad is a Good Ad
- Confusing Creativity with Mission
- McKinnell's New Gig: Male Model
- PhRMA Intern Tackles Terrorists!
- Blockbuster or Ballbuster?
- A Milestone Is Reached!
- Rozerem Ads Dis Lincoln, Show Beaver
- Blockbuster or Ballbuster?
- How to Piss Off KOLs
- More Reminder Ad Sightings
- Why Drug Companies Promote Off-Label
- Whose Data Is It Anyway?
- Disease Awareness or "Disease Mongering?"
- Clash!
- DTC without the Risk
- Sales Reps Make Poor Spokespeople
- Generation X Pharma Reps
- Cialis Blog Shut Down
- Cialis Blog -- Shame on Lilly ICOS
- Gifts That Keep on Giving
- Jerry Hall, Women and Pharma Marketing
- Sexy Reps Sell Rx
- Fake Pharma Advertising
- Movies and Drugs: Same Blockbuster Mentality
- Internet Marketing: Risks Ahead
- Deconstructing Frist on DTC
- Peter Rost: Pharma's Black Knight
- PEED: A New Viagra Franchise?
- The Two Bobs: Enzyte vs. Viagra
- John Mack Rebuffs Merck’s CEO Offer
- Pharma Marketing Mensa Invitational
- FDA Advisory Panels: Elephants in the Room
- Who Should Pay for Merck's Obstructionism?
- The End of DTC as We Know It
|